Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $50.8 million.

  • Centessa Pharmaceuticals' Cash & Equivalents fell 87.14% to $50.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.8 million, marking a year-over-year decrease of 87.14%. This contributed to the annual value of $383.2 million for FY2024, which is 199.32% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Cash & Equivalents stood at $50.8 million for Q3 2025, which was up 14.85% from $44.2 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Cash & Equivalents high stood at $544.5 million for Q1 2022, and its period low was $44.2 million during Q2 2025.
  • Moreover, its 3-year median value for Cash & Equivalents was $128.0 million (2023), whereas its average is $175.3 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 199.32% in 2024, then plummeted by 87.14% in 2025.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Cash & Equivalents stood at $393.6 million in 2022, then slumped by 67.48% to $128.0 million in 2023, then surged by 199.32% to $383.2 million in 2024, then tumbled by 87.14% to $50.8 million in 2025.
  • Its Cash & Equivalents was $50.8 million in Q3 2025, compared to $44.2 million in Q2 2025 and $105.2 million in Q1 2025.